Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Designer Drugs: Over the Counter Killers Jennifer L. Nelson, PharmD, BCPP Parkland Health and Hospital System Pharmacist Objectives At the completion of this program, the participant will be able to: • Describe drug abuse patterns and trends among youth and adult residents in Texas. • Differentiate between the presenting symptoms of the novel drugs of abuse and develop a treatment plan for each drug. • State the changes in the Texas Prescription Monitoring program. • Explain the opportunities for pharmacist involvement in Naloxone programs. Pharmacy Technician Objectives At the completion of this program, the participant will be able to: • Describe drug abuse patterns and trends among youth and adult residents in Texas. • Differentiate the presenting symptoms of the novel drugs of abuse. • State the changes in the Texas Prescription Monitoring program. Substance Abuse Trends in Texas • Methamphetamine • Forensic laboratories: outranks both cocaine and cannabis • #1 in Dallas, #2 in Houston and #4 in El Paso • Seizures along Texas border up by 260% (western part) and 420% on the lower border • Heroin • Younger users and a wider variety of ethnicities • Seizures along western part of the Border up 352% • New Mexican “white” heroin Maxwell JC. Substance Abuse Trends in Texas: June 2014. Proceedings of the Community Epidemiology Work Group, June 2014. Substance Abuse Trends in Texas • Cocaine • Decrease in abuse • Fewer coca bushes being grown in the Andes, product being diverted to Europe • Cannabis • Drought in Mexico, gang warfare and increased border protection limited Mexican cannabis increase in home-grown and hydroponic cannabis • Higher quality cannabis from Colorado • Electronic cigarettes used for “vaping” of hash oil and “shatter” • Synthetic Cannabis • Many banned in Texas on September 1, 2011 • US banned more on July 9, 2012 • Importing chemicals from Mexico Maxwell JC. Substance Abuse Trends in Texas: June 2014. Proceedings of the Community Epidemiology Work Group, June 2014. Substance Abuse Trends in Texas • “Other Opiates” • Pill mills • Tramadol • Fentanyl • Patches vs. Powder • PCP • Abused more by females • MDMA/Ecstasy • Decreased use of “molly”: but has a higher potency Maxwell JC. Substance Abuse Trends in Texas: June 2014. Proceedings of the Community Epidemiology Work Group, June 2014. Substance Abuse Trends in Texas Youth • Alcohol • Primary drug of abuse in Texas • 51% of Texas secondary school students (grades 7-12) had every used alcohol • 25% had consumed alcohol in the last month • Binge drinking: 9% reported • New methods of use: inhaling or “smoking” alcohol • Cannabis • Decrease in Mexican imports, increase in indoor and hydroponic growth • Increase in potency (3.06% to 11.8%) • New methods of use • blunt cigars, flavored “papers” and “cones” • Electronic cigarettes filled with tobacco or hash oil (“wax”, “shatter” or “budder”) • Brownies or cookies containing hash oil Maxwell JC. Substance Abuse Trends in Texas: June 2014. Proceedings of the Community Epidemiology Work Group, June 2014. Substance Abuse Trends in Texas Youth • Synthetic Cannabis • 7% of students have ever used • Heroin • Use is growing among teenagers and young adults • Increased use: Powdered “cheese heroin”, “Mexican Queso” • Primary types in Texas: Mexican black tar and powdered brown • Cocaine • Decrease in use • Increased demand for cocaine in Europe • Decline in production • Addition of levamisole: filler that will dilute the potency • Transitioning to methamphetamine (easier to obtain) • Cocaine inhalers are more likely younger users Maxwell JC. Substance Abuse Trends in Texas: June 2014. Proceedings of the Community Epidemiology Work Group, June 2014. Misuse vs. Abuse • Misuse • A drug is used for purposes it is not intended for • Not necessarily looking for a “high” • Signs of drug misuse • Taking a dose at the wrong time • Forgetting to take a dose • Stopping medication too soon • Accepting prescription medication from a friend • Taking drugs for reasons other than what they were prescribed for • Abuse • Use the drug for other than it’s prescribed AND for feelings of getting a “high” • Signs of drug abuse • Using a drug to “get high” • Using without a prescription • Exceeding a recommended dose • Chronic or repeated abuse • Developed tolerance Prescription Drug Abuse • Gabapentin • Structurally related to GABA • Used by patients in methadone programs • Codeine or Hydrocodone cough syrup • “lean” or “syrup” • Mixed with soft drinks or cocktails • Can also be used undiluted • Benzodiazepines • Alprazolam • Pseudoephedrine • Used to produce very small amounts of methamphetamine ~ 1% • Dextromethorphan • Produce hallucinogenic effects when taken in large quantities Mersfelder TL, Ann Gabapentin: Abuse, dependence and withdrawal. Pharmacother. 2016, 229-233 Quetiapine Misuse/Abuse • Quetiapine is approved for the treatment of Schizophrenia and acute episodes of Bipolar disorder. May also be used for adjunctive treatment of depression. • 13.6 million Americans have a mental health disorder listed above • >54 million prescriptions written per year • Side effects: constipation, nausea, orthostasis, increased appetite, weight gain, and sedation • Produces calming and hallucinogenic effects • Baby heroin, Squirrel, Q-ball, Quell, Snoozeberries and Susie-Q • Misuse through crushing and snorting • Dissolve into water-based solutions and inject intravenously • AstraZeneca released extended-release version to help deter abuse www.dualdiagnosis.org Addiction • A state in which an organism engages in a compulsive behavior, even when faced with negative consequences • Natural rewards vs. artificial rewards • Reward pathway: ventral tegmental area (VTA), nucleus accumbens and the prefrontal cortex Pompei P, et al. The “Legal Highs” of Novel Drugs of Abuse. J Drug Abuse. 2015, 2:2 Addiction • Properties of addiction • Directly related to the reinforcing properties of a drug • Related to the effects of the drug itself • Psychoactive drugs alter normal neurochemical processes • Mimic the action of the neurotransmitter • Alter the activity of a receptor • Acting on the activation of second messengers • Directly affecting intracellular processes that control normal functioning Pompei P, et al. The “Legal Highs” of Novel Drugs of Abuse. J Drug Abuse. 2015, 2:2 Novel Psychoactive Substances • Synthetic drugs • Created using man-made chemicals rather than natural ingredients • Designer drugs • A synthetic version of an illegal drug that is slightly altered in order to avoid classifying it as illegal • Sold in various locations • Internet, certain stores as “herbal smoking blends” • Labeled as “not for human consumption” • Users are unsure of what the drug may contain Andrabi S, et al. New drugs of abuse and withdrawal syndrome. Emerg Med Clin N Am. 2015: 779-795 Novel Psychoactive Substances • >650 new designer drugs submerged on Europe in the past 10 years • Mostly produced in China and South East Asia New Psychoactive Substances 400 200 0 2010 2011 2012 2013 2014 Novel Psychoactive Substances Classifications • Psychotropic Effect: Stimulants, Empathogens/Entactogens or Hallucinogens • Chemical Family: Phenethylamines, Amphetamines, Cathinones, Piperazines, Pipradrols/Piperidines, Aminoindanes, Benzofurans, and Tryptamines • Synthetic cannabinoids: include a large number of agents which act upon CB1 receptor (have hallucinogenic and stimulant properties) • Usually classified based on their pharmacological properties • Dopaminergic, noradrenergic or serotonergic pharmacologic effects Pompei P, et al. The “Legal Highs” of Novel Drugs of Abuse. J Drug Abuse. 2015, 2:2 Novel Psychoactive Substances Synthetic Cannabinoids • “Spices”: herbal mixtures • Many substance names start with the initials of the chemist (i.e. AM followed by numbers) • Act as agonists at the CB1 receptor • Produce similar effects and toxicity to tetrahydrocannabinol (THC) • Not detective by UDS for THC • More severe psychosis and agitation, and increased sympathomimetic effects (due to lack of cannabidiol) • Common symptoms: agitation, aggression, paranoid thinking and anxiety • 2nd generation: in US and Europe: severe toxicity seizures, cardiac toxicity, acute kidney injury Andrabi S, et al. New drugs of abuse and withdrawal syndrome. Emerg Med Clin N Am. 2015: 779-795 Synthetic Cannabinoids Continued • 2013 US government report: Emergency department visits in 2011 increased by 2.5 times • 2014: Texas dealer of K2 was linked to 120 overdoses in Austina nd Dallas in one week alone • Multiple car accidents linked to smoking of synthetic marijuana • Effects on the Mind • Confusion, extreme anxiety, severe paranoia, delusions, hallucinations • Effects on the Body • Nausea, vomiting, acute kidney injury, increased blood pressure, convulsions, seizures, strokes “Global Synthetic Drugs Assessment,” UN Office on Drugs and Crime, 2014 Novel Psychoactive Substances Continued • Synthetic Cathinones • Contain a ketone group at the β-position of the amphetamine • Most common: mephedrone, methylone and MDPV • Others: ethylone, methedrone, naphyrone, flephedrone, 3fluoromethcathinone (3-FMC), pentylone, buphedrone, α-PVP, etc • Can have effects similar to cocaine but also MDMA • Psychotropic effects similar to MDMA but with enhanced psychostimulation similar to cocaine • Toxicity (similar to amphetamine): hypertension, hyperthermia, euphoria, locomotor activation and hallucinations • Noted to be more addictive then cocaine • Ring substituted phenethylamines and amphetamines (2-C and 2-D series) • • • • Examples: 2C-B and 2C-I as well as DOM, DOB and DOI Increased hallucinogenic properties Intoxication: hallucinations, Nausea, tachycardia, agitation, ergotism 25I-NBOMe: Severe and fatal intoxications: agitation, hallucinations, seizures, hyperthermia Andrabi S, et al. New drugs of abuse and withdrawal syndrome. Emerg Med Clin N Am. 2015: 779-795 Bath Salts • • • • Group of similar substance Referred to as synthetic stimulants Most of the substance are banned in the US Users may snort, inject, take rectally, mix it with food/drink, “bombing”, or smoke it • Effects on the Mind • Insomnia, euphoria evolving to paranoia, nightmares, hallucinations, suicidal thoughts, violent behavior • Effects on the Body • Mephedrone stink, fever, sexual dysfunction, nosebleeds, dizziness, chest pain and heart attacks, brainstem herniation, seizures “Global Synthetic Drugs Assessment,” UN Office on Drugs and Crime, 2014 Novel Psychoactive Substances Continued • Kratom • Opioid-like tropical tree from Southeast Asia • Used to alleviate musculoskeletal pain, increase energy,appetite and sexual desire • Thought to be a “natural alternative” for chronic pain and opioid withdrawal • Smoked, ingested or brewed • Adverse effects: nausea, vomiting, constipation, anorexia and palpitations • Acetyl Fentanyl • • • • Opioid analgesic Similar to fentanyl Transdermal patch or IV Euphoria, altered mood, miosis, constipation and respiratory depression Pompei P, et al. The “Legal Highs” of Novel Drugs of Abuse. J Drug Abuse. 2015, 2:2 Novel Psychoactive Substances Continued • Salvia • Active compound: salvironin A • Selective high efficacy kappa-opioid receptor agonist • Causes hallucinogenic-like, depression-like and anxiety-like states • NBOMe • Most common: 25C-NBOMe • Legally replaced LSD • Administration route: buccal, sublingual, nasal, oral, parenteral, rectal and inhalation • Symptoms: nausea, vomiting, dizziness, diarrhea, headaches and hallucinations Pompei P, et al. The “Legal Highs” of Novel Drugs of Abuse. J Drug Abuse. 2015, 2:2 Novel Psychoactive Substances Continued • Phenethylamines and Amphetamines • Amphetamine derived MDMA is one of the most widely used recreational drugs • Prototypical empathogen or entactogen produces empathy or “being touched” • Enhances sociability • Para-(4)-phenyl-substituted (serotonergic) amphetamines • Paramethoxyamphetamine (PMA) and Paramethoxymethamphetamine (PMMA) • Typically sold as ecstasy • Higher morbidity and mortality hyperthermia (stronger then MDMA) • Potent noradrenaline and serotonin transporter inhibitors • Examples: 4-methylthioamphetamine (4-MTA) and methedrone (β-keto-PMMA) Andrabi S, et al. New drugs of abuse and withdrawal syndrome. Emerg Med Clin N Am. 2015: 779-795 Novel Psychoactive Substances Continued • Benzofurans and Benzodifurans • Ring substituded amphetamines • Structurally related to MDMA • Effects related to MDMA but more intense • Examples: 6-APB and 5-APB • ADE: nausea, sympathomimetic stimulation and agitation • Also known as the “fly” drugs (bromo-dragon fly, 2C-B-fly) • Paranoia, agitation, tachycardia and hyperthermia • Piperazines • Found in ecstasy as substitutes for MDMA • Examples: m-CPP and TFMPP • Less desirable psychotropic effects and more adverse effects • Dysphoria, anxiety and nausea • Benzylpiperazine (BZP): toxicity hallucinations, agitation, seizures and hyperthermia Andrabi S, et al. New drugs of abuse and withdrawal syndrome. Emerg Med Clin N Am. 2015: 779-795 Novel Psychoactive Substances Continued • Aminoindanes • Examples: MDAI and 5-IAI • Less neurotoxic than MDMA • Pipradrols/Piperidines • “Ivory Wave”: contains 2-DPMP or D2PM • Similar to methylphenidate • Long-lasting clinical toxicity: sympthomimetic stimulation, hypertension, agitation, hallucinations and insomnia • Tryptamines • • • • • • Natural tryptamine: psilocybin and dimethyltryptamine (DMT) Ergolines: include protypic hallucinogen: LSD Examples: alpha-methyltryptamine (AMT) and 4-HO-MET Serotonin syndrome and sympathomimetic toxicity may occur Hallucinogenic properties (typically visual) Usually nonaddictive Andrabi S, et al. New drugs of abuse and withdrawal syndrome. Emerg Med Clin N Am. 2015: 779-795 Novel Psychoactive Substances Treatment Substance Leading Acute Toxicity PMA Serotonergic toxidrome, hyperthermia, nausea, seizures, fatalities Mephedrone, methylone Sympathomimetic toxidrome, agitation, vomiting, psychosis, chest pain, seizures, insomnia MDPV, α-PVP Psychosis, agitation, combative behavior, sympathomimetic toxidrome, chest pain, prolonged insomnia BZP Mostly sympathomimetic toxicity, agitation, anxiety “fly” drugs Psychosis, agitation, hyperthermia, sympathomimetic toxicity, vasospasm, limb pain/ischemia, seizures, fatalities AMT Serotonergic and sympathomimetic toxidrome, psychosis, agitation, hyperthermia, nausea Synthetic cannabinoids Psychosis, agitation, anxiety, sympathomimetic toxidrome, chest pain, myocardial infarction, renal injury, seizure, vomiting Novel Psychoactive Substance Treatment Continued • Establish safety • Many have an altered sensorium • Poor historians • Ensure patient’s airway and adequate breathing • CNS depression • Treatment is mainly supportive • Heart rate, blood pressure and body temperature • Hypertension and Hypotension have both been seen • Hypertension nitrates (avoid β-blockers) • Laboratory tests: electrolytes, creatine kinase, liver enzymes and cardiac enzyme • Treatment of a sympathomimetic toxidrome • Benzodiazepines and fluid replacement Pompei P, et al. The “Legal Highs” of Novel Drugs of Abuse. J Drug Abuse. 2015, 2:2 Novel Psychoactive Substance Treatment Continued • Consider Naloxone administration • Physical cooling and relaxation may be needed in severe hyperthermia cases • Behavioral therapies • Yet to be tested • Once patient is in recovery, a thorough assessment should occur • Trace the history of the elicit substance Pompei P, et al. The “Legal Highs” of Novel Drugs of Abuse. J Drug Abuse. 2015, 2:2 Opioid Overdose • Examples of opioids: morphine, heroin, oxycodone and methadone • Signs and symptoms: “opioid overdose triad” • • • • Respiratory depression Decreased level of consciousness Pinpoint pupils Other symptoms • Seizures and muscle spasms • Effects influence by: dose, tolerance and presence of active metabolites • Treatment • Identify the specific drug, dose and formulation • Identify co-exposures • Administration of Naloxone Texas Pharmacist Naloxone Standing Order • Naloxone • µ-opioid receptor inverse agonist • Antagonist action • Used to block the effects of opioids • Reverses the depression of the central nervous system and respiratory system caused by opioids • Competes for the opiate receptor sites within the CNS, preventing the action of both endogenous and xenobiotic opiates on these receptors • Poorly absorbed orally • Intravenous: effect seen within 2 minutes • Intramuscular: effect seen within 5 minutes • Dose: 0.4-2mg, may repeat doses every 2 minutes until the max dose of 10mg has been reached Naloxone Hydrochloride. The American Society of Health-System Pharmacists. Retrieved November 5, 2016. Naloxone Standing Order • A standing order is a physician’s order that can be carried out by other health care workers when predetermined conditions have been met. • A doctor with prescriptive authority issues a written order that naloxone can be distributed by designated people to those who meet the criteria outlines in the document • Can receive naloxone without ever meeting the doctor who prescribed it • Statewide written order • Physician General issues a statewide written order that naloxone can be distributed by designated people • >50% of the US states now have naloxone standing order programs http://naloxoneinfo.org/case-studies/standing-orders Naloxone Access and Good Samaritan Laws • 2001: New Mexico became the first state to amend its laws to improve naloxone administration • 2014: >150,000 laypeople had received training and naloxone kits • Reported reversing >26,000 overdoses • June 22, 2015 • 46 other states and the District of Columbia made laws improving access • June 22, 2016 • All but three states (Kansas, Wyoming, Montana) had passed legislation designed to improve naloxone access https://www.networkforphl.org/_asset/qz5pvn/network-naloxone-10-4.pdf Naloxone Access and Good Samaritan Laws https://www.networkforphl.org/_asset/qz5pvn/network-naloxone-10-4.pdf Saving Lives Initiative • Includes allowing pharmacists to administer epinephrine in an emergency situation • Senate Bill 1462 by Sen. Royce West (D-Dallas) • Allows authorized medical personnel to prescribe naloxone either directly to a third-party patient or through a standing order • Created a physician-signed standing order (statewide prescription) • Highest risk are the elderly and medically ill who are already medically compromised. TPA’s Naloxone Standing Order Now Available. Retrieved from http://www.texaspharmacy.org/news/303222/TPAsNaloxone-Standing-Order-Now-Available.htm. November 2016 Texas Pharmacist Naloxone Standing Order • To facilitate the prescribing of opioid antagonists • To combat the effects of opioid overdose • Formulations of opioid antagonist • • • • • Intramuscular Naloxone Naloxone Auto-Injector Intranasal Naloxone Naloxone Nasal Spray Any other opioid antagonist formulation permitted under the law • May dispense any other items necessary for administration • Syringes and mucosal atomization devices TPA’s Naloxone Standing Order Now Available. Retrieved from http://www.texaspharmacy.org/news/303222/TPAsNaloxone-Standing-Order-Now-Available.htm. November 2016 Texas Pharmacist Naloxone Standing Order • Dispense to: a person at risk of overdose; also to a family member, friend or other person in a position to assist such a person • Prior to dispensing • Pharmacist shall complete and obtain a certificate of completion of a one hour Texas accredited course provided by an Accreditation Council for Pharmacy Education which includes: • When a pharmacist should or should not dispense • How to work with the patient in selecting which opioid antagonist to dispense • When to administer • Standing order shall be maintained at the pharmacy • Pharmacist must maintain an active license and remain in good standing with the TSBP TPA’s Naloxone Standing Order Now Available. Retrieved from http://www.texaspharmacy.org/news/303222/TPAsNaloxone-Standing-Order-Now-Available.htm. November 2016 Distribution, Possession and Administration • Permits groups such as nonprofits, drug treatment centers and other organizations to distribute naloxone • Allows any person to possess naloxone (even if they do not have a prescription for it) • Allows any person, who acts in good faith and with reasonable care, to administer naloxone • Immune from criminal prosecution, civil liability and sanction under professional licensing statutes Naloxone Pricing • Naloxone has increased by as much as 17-fold since 2014 • Naloxone auto-injector $4,500 (previous wholesale price $690) • Insurance coverage • Texas Medicaid does cover all formulations of naloxone Krokodil (desomorphine) • Noted as the MOST devastating designer drug on the street market • Used as a pain reliever in Switzerland in the early 1930s • Appeared on the black market in the early 2000s • Reports of over 100,000 people having injected the drug in 2011 • Schedule I controlled substance in the US • Subject to annual aggregate manufacturing quotas • In 2014 the quota was 5 grams • Entirely user made and distributed • Regulated: codeine and hydrochloric acid • Unregulated: gasoline, paint thinner, iodine and red phosphorous (from matchstick heads) Alves EA, et al. Forensic Sci Int. 2015 Apr; 249: 207-213. Krokodil • Transient opiate like high • Injected every couple hours • Onset of effect ~ 2-3 minutes • Euphoria lasts between 1.5-2 hours • 30,000 people killed each year in Russia • Users are reported to rarely live past a year after they start taking it • Life expectancy of three years maximum Alves EA, et al. Forensic Sci Int. 2015 Apr; 249: 207-213. Krokodil Signs and Symptoms Short Term Decrease in overall health Weight loss Lethargy Inability to remain awake Depression Anxiety Flu-like symptoms Long Term Blood vessel damage Skin and soft tissue infections Osteomyelitis Pneumonia Meningitis Memory loss Organ failure Alves EA, et al. Forensic Sci Int. 2015 Apr; 249: 207-213. Krokodil Haskin A, Kim N, Aguh C. JAAD Case Rep. 2016 Mar; 2(2): 174-176 Krokodil Treatment • Medically monitored – inpatient admission • Intensive medical attention in addition to addiction treatment • Symptoms may last up to a month after discontinuation • Usual symptoms: insomnia, nausea, diarrhea, extreme muscle cramping, depression, body aches and overall sickness • Residual symptoms: vacant gaze, speech impediment and erratic movements • Opioid antagonist can be utilized Alves EA, et al. Forensic Sci Int. 2015 Apr; 249: 207-213. Questions??? References • Maxwell JC. Substance Abuse Trends in Texas: June 2014. Proceedings of the Community Epidemiology Work Group, June 2014. • Mersfelder TL, Nichols WH. Ann Gabapentin: Abuse, dependence and withdrawal. Pharmacother. 2016, 229-233 • Seroquel Abuse. Retrieved from http://www.dualdiagnosis.org/seroquel-abuse/. November 2016 • “Global Synthetic Drugs Assessment,” UN Office on Drugs and Crime, 2014. • Andrabi S, Greene S, Moukkadam N, Li B. New drugs of abuse and withdrawal syndrome. Emerg Med Clin N Am. 2015: 779-795 • Pompei P, Micioni Di Bonaventura MV, Cifani C. The “Legal Highs” of Novel Drugs of Abuse. J Drug Abuse. 2016, 2:2. • Naloxone Hydrochloride. The American Society of Health-System Pharmacists. Retrieved November 5, 2016. • Naloxone overdose and Good Samaritan Laws. Retrieved from https://www.networkforphl.org/_asset/qz5pvn/network-naloxone-10-4.pdf • Standing orders. Retrieved from http://maloxoneinfo.org/case-studies/standing-order. November 2016 • TPA’s Naloxone Standing Order Now Available. Retrieved from http://www.texaspharmacy.org/news/303222/TPAs-Naloxone-Standing-Order-NowAvailable.htm. November 2016 • Alves EA, et al. The harmful chemistry behind krokodil (desomorphine) synthesis and mecahnisms of toxicity. Forensic Sci Int. 2015 Apr; 249: 207-213. • Haskin A, Kim N, Aguh C. A new drug with a nasty bite: A case of krokodil-induced skin necrosis in an intravenous drug user. JAAD Case Rep. 2016 Mar; 2(2): 174-176